A Framework for Developing and Evaluating a Monitoring Strategy

Evidence-based Medical Monitoring: From Principles to Practice

Volumn , Issue , 2008, Pages 15-30

  Mant, David ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Disorder; Intervention; Screening strategy; Sequential results; Strategic options

Indexed keywords

EID: 78649760434     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470696323.ch2     Document Type: Chapter

References (15)

1. Anonymous. Cancer of the cervix: death by incompetence. Lancet 1985; ii: 363-4.
2. Mant D. Prevention. Lancet 1994; 344: 1343-6.
3. Pearce SH. Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK. Clin Endocrinol 2004; 61: 589-94.
4. Grunfeld E, Mant D, Yudkin P, et al. Routine follow-up of breast cancer in primary care: a randomised trial. BMJ 1996; 313: 665-9.
5. Renehan AG, Egger M, Saunders MP, O'Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and metaanalysis of randomised trials. BMJ 2002; 324: 813.
6. Aronson JK. Biomarkers and surrogate endpoints. Br J Clin Pharmacol 2005; 59: 491-4.
7. Glasziou P, Irwig L, Mant D. Monitoring in chronic disease: a rational approach. BMJ 2005; 330: 644-8.
8. Yoos HL, Kitzman H, McMullen A, Henderson C, Sidora K. Symptom monitoring in childhood asthma: a randomized clinical trial comparing peak expiratory flow rate with symptom monitoring. Ann Allergy Asthma Immunol 2002; 88: 283-91.
9. Wald N. Use of MoMs. Lancet 1993; 341: 440.
10. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: systematic review and meta-analysis. Genet Med 2005; 7: 97-104.
11. Walton RT, Harvey E, Dovey S, Freemantle N. Computerised advice on drug dosage to improve prescribing practice. Cochrane Database Syst Rev 2001; (1): CD002894.
12. Pierach CA. Did Ulysses have porphyria? J Lab Clin Med 2004; 144: 7-10.
13. Aronson J, Ferner R. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 2003; 327: 1222-5.
14. Skeie S, Thue G, Sandberg S. Use and interpretation of HbA1c testing in general practice. Implications for quality of care. Scand J Clin Lab Invest 2000; 60: 349-56.
15. Reynolds DJ, Aronson JK. ABC of monitoring drug therapy. Cyclosporin. BMJ 1992; 305: 1491-4.